Conferences

Catalog

Abstracts

Calendar

North Carolina Hematologic Malignancies Symposium 2026: Evidence-Based Updates and Clinical Decision-Making in Lymphoma, CLL, Myeloma, AML, and MPNs

Accreditation: 3.50 Nursing Contact Hours | 3.50 ABIM MOC II | 3.50 AMA PRA Category 1 Credit™ | 3.50 ACPE Pharmacy

Venue: Washington Duke Inn & Golf Club, 3001 Cameron Blvd, Durham, NC, 27705, United States

Start Date: October 16, 2026

Overview

Trusted by Thousands of Attendees
Across Our Events

29+

Email if you have questions

Our Speakers

Planning Committee

Binay Shah, MD, MHA

Conference Director

Binaytara

Debbie Stephens, DO

Conference Co-Chair

University of North Carolina

Joshua Zeidner, MD

Conference Co-Chair

University of North Carolina

Nilanjan Ghosh, MD, PhD

Planning Committee

Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine

Lindsay Rein, MD

Planning Committee

Duke University

Sascha Tuchman, MD

Planning Committee

University of North Carolina at Chapel Hill

Faculty

Rakhee Vaidya, MD

Topic Presenter

Atrium Health Wake Forest

Brandi Reeves, MD

Topic Presenter

University of North Carolina at Chapel Hill

Matthew McKinney, MD

Topic Presenter

Duke University School of Medicine

Andrea Sitlinger, MD

Topic Presenter

Duke Cancer Center

Bejal Kikani, FNP, NP

Topic Presenter

UNC Health

Franklin Chen, MD

Topic Presenter

Novant Health Cancer Institute

Ryan Wayne Jacobs, MD

Topic Presenter

Atrium Health Levine Cancer Institute

Cristiana Costa, DO

Topic Presenter

Duke University

Eben Lichtman, MD

Topic Presenter

University of North Carolina

Madelyn Burkart, MD

Topic Presenter

Atrium Health Wake Forest

Tamara Moyo, MD PhD

Topic Presenter

Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine

John Preston Claiborne, MD

Topic Presenter

Duke University

Daniel Peters, MD

Topic Presenter

Advocate Health

Lacey Williams, MD

Topic Presenter

University of North Carolina

Ara Metijan, MD

Topic Presenter

Duke University School of Medicine, Duke Cancer Institute

Agenda

Friday, October 16th, 2026

All timings are in Eastern Time (EDT, GMT-04:00) time.

08:00 AM - 08:30 AMRegistration, Breakfast, & Exhibits (President II)

08:30 AM - 08:35 AMWelcome (President III & IV)

08:35 AM - 08:50 AMBinaytara’s Efforts in Improving Cancer Care Disparities (non-CME accredited) - Bhawana Srivastava, MBA (President III & IV)

08:50 AM - 09:35 AMSession 1: Lymphoma (President III & IV)

Session Chair: Nilanjan Ghosh, MD, PhD

08:50 AM - 09:00 AM

Treatment of Relapsed or Refractory Marginal Zone Lymphoma – Rakhee Vaidya, MD

09:00 AM - 09:10 AM

Second Line Treatment of Diffuse Large B-Cell Lymphoma – Tamara Moyo, MD PhD

09:10 AM - 09:20 AM

Treatment of Relapsed or Refractory Follicular Lymphoma – Matthew McKinney, MD

09:25 AM - 09:35 AM

Panel Discussion

Moderators:

Nilanjan Ghosh, MD, PhD

Panelists:

Rakhee Vaidya, MD; Tamara Moyo, MD PhD; Matthew McKinney, MD

09:35 AM - 09:45 AMBreak & Exhibits (President II)

09:45 AM - 10:30 AMSession 2: CLL (President III & IV)

Session Chair: Debbie Stephens, DO

09:45 AM - 09:55 AM

Should We Use Pirtobrutinib in Frontline Treatment of CLL? – Andrea Sitlinger, MD

09:55 AM - 10:05 AM

When Should We Use PVR For Relapsed/Refractory CLL? – Ryan Wayne Jacobs, MD

10:05 AM - 10:15 AM

When Should We Use MRD to Guide Therapy for CLL? – Bejal Kikani, FNP, NP

10:15 AM - 10:30 AM

Panel Discussion

Moderators:

Debbie Stephens, DO

Panelists:

Ryan Wayne Jacobs, MD; Bejal Kikani, FNP, NP; Andrea Sitlinger, MD

10:30 AM - 11:15 AMSession 3: Multiple Myeloma (President III & IV)

Session Chair: Sascha Tuchman, MD

10:30 AM - 10:40 AM

What's the Real Role for Plasma Exchange in Cast Nephropathy? – Cristiana Costa, DO

10:40 AM - 10:50 AM

Who With Myeloma Really Needs IVIG? – Eben Lichtman, MD

10:50 AM - 11:00 AM

What's the Optimal Way to Treat Bone Disease and Enhance Bone Health in Myeloma? – Franklin Chen, MD

11:00 AM - 11:15 AM

Panel Discussion

Moderators:

Sascha Tuchman, MD

Panelists:

Cristiana Costa, DO; Eben Lichtman, MD; Franklin Chen, MD

11:15 AM - 12:15 PMLunch & Exhibits (President II) - Product Theater Sponsored by BMS (Biddle Room)

12:15 PM - 01:00 PMSession 4: AML (President III & IV)

Session Chair: Joshua Zeidner, MD

12:15 PM - 12:23 PM

Debate: HMA/Venetoclax is the New Standard of Care for Newly Diagnosed AML patients Irrespective of Age (Pro) – Lacey Williams, MD

12:23 PM - 12:31 PM

Debate: HMA/Venetoclax is the New Standard of Care for Newly Diagnosed AML Patients Irrespective of Age (Con) – Madelyn Burkart, MD

12:31 PM - 12:39 PM

Debate: HMA/Venetoclax Triplets Will be the Standard of Care for All Older AML patients in the Future? (Pro) – Daniel Peters, MD

12:39 PM - 12:47 PM

Debate: HMA/Venetoclax Triplets Will be the Standard of Care for All Older AML Patients in the Future? (Con) – John Preston Claiborne, MD

12:47 PM - 01:00 PM

Panel Discussion

Moderators:

Joshua Zeidner, MD

Panelists:

John Preston Claiborne, MD; Lacey Williams, MD; Daniel Peters, MD; Madelyn Burkart, MD

01:00 PM - 01:30 PMSession 5: Myeloproliferative Neoplasms (President III & IV)

Session Chair: Lindsay Rein, MD

01:00 PM - 01:10 PM

Essential Thrombocytosis - Interferons and Novel Therapeutics Strategies – Brandi Reeves, MD

01:10 PM - 01:20 PM

Polycythemia Vera - Recent Approvals and Novel Approaches – Lindsay Rein, MD

01:20 PM - 01:30 PM

Acquired von Willebrand Disease and Other Classical Hematologic Complications of MPNs – Ara Metijan, MD

01:30 PM - 01:45 PM

Panel Discussion

Moderators:

Lindsay Rein, MD

Panelists:

Ara Metijan, MD; Brandi Reeves, MD

01:45 PM - 01:45 PMClosing Remarks & Adjourn

About North Carolina Hematologic Malignancies Symposium 2026: Evidence-Based Updates and Clinical Decision-Making in Lymphoma, CLL, Myeloma, AML, and MPNs

Overview

Faculty and committee

Our Speakers

Planning Committee

Faculty

Conference program and agenda

Agenda

Venue and map

Accreditations and continuing education

Registration and pricing

Exhibitors and sponsorship